Overview

Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. (Ineox Study)

Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
0
Participant gender:
All
Summary
This study evaluates in a group of people with DM 1 the influence in parameters of oxidative stress of the treatments with the different current analogs of insulin
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Treatments:
Insulin
Insulin Aspart
Insulin degludec, insulin aspart drug combination
Insulin Glargine
Insulin glulisine
Insulin Lispro
Insulin, Globin Zinc
Insulin, Long-Acting
Criteria
Inclusion Criteria:

- Age between 18 years and 65 years (inclusive).

- DM1 of more than two years of evolution with habitual follow-up in the Diabetes Unit
of the University Regional Hospital of Malaga.

- HbA1c ≤ 10%

- Intensive treatment with basal MDI - Bowl for more than 12 months prior to the start
of study.

- Gives informed consent.

Exclusion Criteria:

- Chronic kidney disease, liver disease, thyroid dysfunction (except hypothyroidism
correctly treated and controlled).

- Pregnancy or pregnancy planning.

- Diabetes mellitus type 2.

- Hyperuricemia (uric acid ≥7 mg / dl at the time of inclusion or current treatment With
allopurinol).

- Absence of collaboration (informed consent).